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1. INTRODUCTION {#irv12495-sec-0006}
===============

Influenza infections are responsible for substantial morbidity during most seasons.[1](#irv12495-bib-0001){ref-type="ref"}, [2](#irv12495-bib-0002){ref-type="ref"}, [3](#irv12495-bib-0003){ref-type="ref"}, [4](#irv12495-bib-0004){ref-type="ref"}, [5](#irv12495-bib-0005){ref-type="ref"}, [6](#irv12495-bib-0006){ref-type="ref"}, [7](#irv12495-bib-0007){ref-type="ref"} Influenza‐associated illnesses are difficult to count because symptoms are non‐specific, diagnostic codes associated with influenza‐related symptoms are broad, and sensitive and specific laboratory testing for influenza is not routine. Many studies have estimated rates of serious complications of influenza infections---including hospitalizations and deaths---with statistical models.[1](#irv12495-bib-0001){ref-type="ref"}, [2](#irv12495-bib-0002){ref-type="ref"}, [3](#irv12495-bib-0003){ref-type="ref"}, [4](#irv12495-bib-0004){ref-type="ref"}, [5](#irv12495-bib-0005){ref-type="ref"}, [6](#irv12495-bib-0006){ref-type="ref"}, [7](#irv12495-bib-0007){ref-type="ref"}, [8](#irv12495-bib-0008){ref-type="ref"}, [9](#irv12495-bib-0009){ref-type="ref"}, [10](#irv12495-bib-0010){ref-type="ref"}, [11](#irv12495-bib-0011){ref-type="ref"} Modeling these outcomes is routine because severe influenza sequelae are uncommon, and confirmation of infection in such patients may be difficult, even with modern diagnostics. By contrast, influenza‐associated outpatient visits are plentiful, so rates of laboratory‐confirmed visits should be easier to document. However, relatively few studies have made population‐based estimates of influenza‐confirmed outpatient visit rates.[12](#irv12495-bib-0012){ref-type="ref"}, [13](#irv12495-bib-0013){ref-type="ref"}, [14](#irv12495-bib-0014){ref-type="ref"}, [15](#irv12495-bib-0015){ref-type="ref"}, [16](#irv12495-bib-0016){ref-type="ref"}, [17](#irv12495-bib-0017){ref-type="ref"} Most have focused on children, typically in a single site.[12](#irv12495-bib-0012){ref-type="ref"}, [14](#irv12495-bib-0014){ref-type="ref"}, [15](#irv12495-bib-0015){ref-type="ref"}, [16](#irv12495-bib-0016){ref-type="ref"}, [17](#irv12495-bib-0017){ref-type="ref"} Often, few influenza‐confirmed cases are reported (range, 90‐372),[12](#irv12495-bib-0012){ref-type="ref"}, [13](#irv12495-bib-0013){ref-type="ref"}, [15](#irv12495-bib-0015){ref-type="ref"}, [17](#irv12495-bib-0017){ref-type="ref"} resulting in wide confidence intervals (CIs) around rate estimates. While a key characteristic of influenza is season‐to‐season variability in intensity and severity, most studies have focused on a few seasons,[12](#irv12495-bib-0012){ref-type="ref"}, [13](#irv12495-bib-0013){ref-type="ref"}, [17](#irv12495-bib-0017){ref-type="ref"}, [18](#irv12495-bib-0018){ref-type="ref"} or reported summary estimates from multiple seasons.[14](#irv12495-bib-0014){ref-type="ref"}, [15](#irv12495-bib-0015){ref-type="ref"}, [16](#irv12495-bib-0016){ref-type="ref"} Finally, studies testing for influenza per protocol are not common,[12](#irv12495-bib-0012){ref-type="ref"}, [13](#irv12495-bib-0013){ref-type="ref"}, [15](#irv12495-bib-0015){ref-type="ref"}, [17](#irv12495-bib-0017){ref-type="ref"} as prospective studies are resource‐intensive. Thus, such studies are rarely conducted in large populations including persons of all ages, in multiple sites, or during multiple influenza seasons.

The 2009 influenza A(H1N1) pandemic highlighted a lack of US population‐based rates of medically attended influenza‐associated illnesses. The Centers for Disease Control and Prevention (CDC) and National Institute of Health estimated pandemic‐associated illnesses, hospitalizations, and deaths,[19](#irv12495-bib-0019){ref-type="ref"}, [20](#irv12495-bib-0020){ref-type="ref"}, [21](#irv12495-bib-0021){ref-type="ref"}, [22](#irv12495-bib-0022){ref-type="ref"} but few estimates of the incidence of influenza‐like outpatient illnesses associated with H1N1pdm09 infection are available.[23](#irv12495-bib-0023){ref-type="ref"} Without consistently made estimates of influenza‐related outpatient visits, the complete health burden of influenza cannot be established.

We used electronic health data from 6 integrated healthcare delivery organizations (hereafter, sites) participating in the CDC‐funded Vaccine Safety Datalink (VSD) project to estimate rates of influenza‐associated outpatient visits. Our analysis included the 2009 pandemic and the 8 preceding influenza seasons. We compared several estimates of influenza‐associated outpatient rates with those derived from 2 concurrently conducted studies testing for influenza with reverse‐transcription polymerase chain reaction (RT‐PCR) assays.

2. METHODS {#irv12495-sec-0007}
==========

2.1. Study population {#irv12495-sec-0008}
---------------------

The VSD was established in 1990 to monitor vaccine safety in the US childhood immunization program.[24](#irv12495-bib-0024){ref-type="ref"}, [25](#irv12495-bib-0025){ref-type="ref"} It has since expanded in size and scope. Currently, there are 8 participating integrated healthcare delivery systems that enroll about 10 million persons of all ages, or \~3% of the US population. Standardized data files with demographic information, enrollment history, healthcare utilization, and mortality data are maintained at each participating site, and accessed via a distributed data model to ensure confidentially; data quality checks are performed weekly to evaluate the quality of vaccination and medical encounter data.[26](#irv12495-bib-0026){ref-type="ref"} An assessment of possible differences between the insured VSD population and the overall US population found no substantial differences by sex, race, ethnicity, or educational attainment; adults aged 55 through 64 years were slightly over‐represented in VSD data.[27](#irv12495-bib-0027){ref-type="ref"} A review of active vaccine adverse event detection systems noted the pioneering role of the VSD, how it has served as a model for systems in other countries, and its continuing innovation in data management and study design.[28](#irv12495-bib-0028){ref-type="ref"}

Individuals enrolled in 6 VSD sites during 2001‐10---Kaiser Permanente Northern California, Kaiser Permanente Colorado, Kaiser Permanente Northwest (Oregon), Kaiser Permanente Southern California, Marshfield Clinic, and Group Health Cooperative---constituted the study population. Study data included demographic and medical information for each enrollee, including age, sex, enrollment dates, vaccination dates, and International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) diagnosis codes assigned to medical encounters, including those in outpatient settings. Outpatient settings included clinics, urgent care clinics, and emergency departments.

2.2. Human subjects {#irv12495-sec-0009}
-------------------

Institutional review boards at each of the 6 sites reviewed and approved the study protocol.

2.3. Viral surveillance data {#irv12495-sec-0010}
----------------------------

Viral data from WHO Collaborating laboratories and National Respiratory and Enteric Virus Surveillance System (NREVSS) laboratories located within the 3 US regions (East North Central, Mountain, and Pacific) that contained the study sites were collected from 2001‐02 through 2009‐10. Laboratories reported weekly the number of influenza tests performed and the number positive for A(H1N1), A(H3N2), and B viruses. The first positive test for A(H1N1)pdm09 was reported during the week ending April 25, 2009,[29](#irv12495-bib-0029){ref-type="ref"} when seasonal influenza isolates were still predominant. A(H1N1)pdm09 became the predominant virus during week 17, ending May 2, 2009. We defined the pandemic as beginning week 17 of 2009, and ending week 26 of 2010. Weekly respiratory syncytial virus (RSV) data were obtained from NREVSS laboratories during the study period. There were 69‐238 hospital‐based, public health, and free‐standing laboratories located in 38‐47 states. They reported weekly the number of specimens tested for RSV by antigen detection and viral isolation methods and the number of positive results.[30](#irv12495-bib-0030){ref-type="ref"}

2.4. ICD‐9‐CM‐coded outpatient visits {#irv12495-sec-0011}
-------------------------------------

We analyzed weekly outpatient visits listing ICD‐9‐CM codes for pneumonia (480‐486), influenza (487‐488), or respiratory diseases (460‐519). If a patient had 2 or more visits listing a code of interest within 7 days, then only the first visit was used in analyses. Data were stratified into 5 age groups (\<2, 2‐17, 18‐49, 50‐64, and ≥65 years) for comparison purposes.

2.5. Models for estimating influenza‐associated outpatient visits {#irv12495-sec-0012}
-----------------------------------------------------------------

We fit age‐ and site‐specific negative binomial regression models to weekly outpatient visits coded for pneumonia or respiratory diseases.[5](#irv12495-bib-0005){ref-type="ref"}, [6](#irv12495-bib-0006){ref-type="ref"}, [7](#irv12495-bib-0007){ref-type="ref"} We considered visits coded specifically for influenza to represent acute influenza infections; thus, visits listing 487‐488 were not included in regression models. Data for the proportions of specimens testing positive by week for A(H1N1), including H1N1pdm09 and seasonal H1N1, A(H3N2), and B viruses, were included in all models. A model can be summarized as: $$\begin{array}{cl}
{Y_{{age} - \!{site}}{(i)}} & {\, = \,\alpha\exp\{\beta_{0} + \beta_{1}{\lbrack t_{i}\rbrack}\, + \,\beta_{2}{\lbrack t_{i}^{2}\rbrack}\, + \,\beta_{3}{\lbrack\sin{(2t_{i}\pi/52.15)}\rbrack}} \\
 & {\quad\, + \,\beta_{4}{\lbrack\cos{(2t_{i}\pi/52.15)}\rbrack}\, + \,\beta_{5}{\lbrack\text{A(H1N1)}\rbrack}\, + \,\beta_{6}{\lbrack\text{A(H3N2)}\rbrack}} \\
 & {\quad\, + \,\beta_{7}{\lbrack B\rbrack}\, + \,\beta_{8}{{\lbrack\text{RSV}\rbrack}\}}} \\
\end{array}$$where *Y* ~age,site~(*i*) was the predicted number of outpatient visits by age group and site during week *i*; α was the offset term, equal to the natural log of the population size for each age group and site; and β~5~ through β~8~ represented coefficients associated with a standardized estimate of the proportions of specimens testing positive for influenza or RSV during a given week in the region corresponding to a site.[7](#irv12495-bib-0007){ref-type="ref"}

To estimate influenza‐associated pneumonia or respiratory, we started with visits predicted by a full model incorporating all viral terms and those predicted by a model in which an influenza covariate was set to 0, as previously described.[7](#irv12495-bib-0007){ref-type="ref"} Weekly site‐ and age‐specific numbers of estimated influenza‐associated outpatient visits for each site were the sum of predicted pneumonia or respiratory visits and visits coded specifically for influenza. Annual age‐specific incidence estimates were calculated as the sum of estimated outpatient visits in that age group divided by the sum of enrollments from the 6 participating sites. We estimated 95% confidence intervals (CIs) for each rate using 2.5th and 97.5th percentiles from a distribution derived from 10 000 bootstrap simulations.[31](#irv12495-bib-0031){ref-type="ref"}

2.6. Comparisons of estimated influenza‐associated outpatient visits with RT‐PCR‐confirmed influenza rates {#irv12495-sec-0013}
----------------------------------------------------------------------------------------------------------

To check the validity and precision of rates estimated as described above, we compared them with rates derived in 2 studies that tested outpatients for influenza infection using RT‐PCR. Marshfield Clinic rate estimates were compared with rates obtained using data from annual influenza vaccine effectiveness (VE) studies conducted there.[32](#irv12495-bib-0032){ref-type="ref"}, [33](#irv12495-bib-0033){ref-type="ref"} In VE studies, patients presenting with acute respiratory symptoms were approached for enrollment; if consented, a respiratory specimen was collected and tested with CDC‐approved real‐time RT‐PCR assays. Data on RT‐PCR‐confirmed influenza visits were available among persons aged ≥50 years from 2005‐06 through 2009‐10; similar data were not available from other sites. Our pandemic rates were compared with those derived from a US influenza surveillance system, the Influenza Incidence Surveillance Project (IISP). IISP began during the 2009 pandemic. It conducted influenza surveillance in 38 outpatient practices in Florida, Iowa, Minnesota, North Dakota, Utah, and Wisconsin and New York City.[22](#irv12495-bib-0022){ref-type="ref"} Estimates of the incidence of influenza‐confirmed influenza‐like illness (ILI) outpatient visits among 272 642 outpatients were made from October 2009 through July 2012. The number of influenza‐associated ILI cases each week was estimated by multiplying the proportion of ILI visits testing positive for influenza by RT‐PCR and the number of ILI patient visits reported during each week. Incidence rates were calculated by dividing numbers of influenza‐associated ILIs by age‐specific denominators representing the outpatient practice population.[23](#irv12495-bib-0023){ref-type="ref"}

3. RESULTS {#irv12495-sec-0014}
==========

From 2001‐02 through 2008‐09, an annual mean of 31 092 specimens (range, 20 145‐48 798) was tested for influenza in US regions that included the participating sites (Table [1](#irv12495-tbl-0001){ref-type="table-wrap"}). Of these, 16.5% tested positive for non‐pandemic viruses. By type and subtype, these proportions were 3.6%, 8.7%, and 4.2% for A(H1N1), A(H3N2), and B viruses, respectively. A total of 171 545 specimens were tested during the pandemic period, and 48 005 (28.0%) tested positive for A(H1N1)pdm09 virus.

###### 

Annual influenza surveillance virus data for pre‐pandemic (2001‐02 through 2008‐09) and pandemic seasons in 3 US regions[a](#irv12495-note-0003){ref-type="fn"}

  Season         Years     No. of specimens Tested   Positive tests for non‐pandemic viruses   Positive tests for A(H1N1)pdm09 virus                                                     
  -------------- --------- ------------------------- ----------------------------------------- --------------------------------------- ------ ------ ----- ------ ------ ------ -------- ------
  Non‐pandemic   2001‐02   21 453                    58                                        0.3                                     2636   12.3   744   3.5    3438   16.0   ---      ---
  2002‐03        20 145    1519                      7.5                                       602                                     3.0    819    4.1   2940   14.6   ---    ---      
  2003‐04        30 882    0                         0.0                                       5273                                    17.1   58     0.2   5331   17.3   ---    ---      
  2004‐05        32 172    4                         0.0                                       3231                                    10.0   2031   6.3   5266   16.4   ---    ---      
  2005‐06        32 576    122                       0.4                                       3582                                    11.0   1151   3.5   4855   14.9   ---    ---      
  2006‐07        48 798    2101                      4.3                                       2022                                    4.1    986    2.0   5109   10.5   ---    ---      
  2007‐08        35 294    1963                      5.6                                       3113                                    8.8    2394   6.8   7470   21.2   ---    ---      
  2008‐09        27 415    2997                      10.9                                      969                                     3.5    1918   7.0   5884   21.5   ---    ---      
  Annual mean    31 092    1095                      3.6                                       2679                                    8.7    1263   4.2   5037   16.5   ---    ---      
  Pandemic       2009‐10   171 545                   764                                       0.4                                     2521   1.5    663   0.4    3948   2.3    48 005   28.0

The East North Central, Mountain, and Pacific US regions in which the 6 participating health systems provided care.

John Wiley & Sons, Ltd

The 6 sites enrolled \~7.7 million persons annually during the study period. An annual mean rate of 28 (95% CI, 18‐53) outpatient visits per 10 000 person‐years was coded specifically for influenza (Table [2](#irv12495-tbl-0002){ref-type="table-wrap"}). For pneumonia/influenza and respiratory outpatient visits, the annual mean rates were 231 (95% CI, 206‐374) and 4846 (95% CI, 4597‐6205) visits per 10 000 person‐years, respectively. The highest annual mean rate of influenza visits occurred among persons aged 2‐17 years (46, 95% CI, 32‐98); the lowest rate occurred among persons aged ≥65 years (10, 95% CI, 6‐22). Rates for pneumonia/influenza and respiratory outpatient visits were highest among children aged \<2 years (676, 95% CI, 588‐968, and 15 385, 95% CI, 13 696‐17 673, respectively), and were lowest among persons aged 18‐49 years (110, 95% CI, 93‐191, and 3819, 95% CI, 3597‐4963, respectively).

###### 

Annual rates of outpatient visits per 10 000 person‐years for 3 categories of respiratory illnesses, by age group, among 6 US healthcare delivery systems

  Season                                             Year      Age group (y)                                                                                                                           
  -------------------------------------------------- --------- --------------- -------- -------- ------ ------ ------ ------ ------ ------ ------ ------ ------ -------- ------ -------- ------ ------ ------
  Influenza[a](#irv12495-note-0004){ref-type="fn"}                                                                                                                                                     
  Non‐pandemic                                       2001‐02   28              13       117      28     15     80     19     8      42     13     6      24     6        4      16       18     9      42
  2002‐03                                            24        10              78       34       13     90     17     6      29     11     4      18     5      2        9      18       7      39     
  2003‐04                                            90        49              334      62       33     147    34     17     69     25     11     54     18     9        51     37       19     87     
  2004‐05                                            29        14              137      29       16     107    22     12     79     18     9      60     9      4        33     21       11     72     
  2005‐06                                            35        26              89       45       26     97     24     15     38     18     11     26     9      5        15     25       15     44     
  2006‐07                                            33        24              60       45       41     74     22     20     35     15     12     22     6      4        11     23       21     35     
  2007‐08                                            59        43              125      70       63     105    63     47     89     45     32     58     16     12       31     53       42     71     
  2008‐09                                            26        21              49       51       46     85     29     21     39     18     13     24     7      5        9      28       23     36     
  Annual mean                                        41        25              124      46       32     98     29     18     53     20     12     36     10     6        22     28       18     53     
  Pandemic                                           2009‐10   276             237      501      325    310    431    166    140    198    105    83     126    40       31     49       173    154    207
  Pneumonia and influenza                                                                                                                                                                              
  Non‐pandemic                                       2001‐02   605             512      1018     266    236    446    103    78     202    197    165    331    427      362    800      216    187    390
  2002‐03                                            606       509             938      254      213    381    92     79     164    189    165    323    423    351      812    208      181    372    
  2003‐04                                            696       588             1154     287      261    392    113    89     205    212    173    362    462    378      853    237      208    411    
  2004‐05                                            650       553             1042     298      257    452    102    84     232    203    169    397    441    365      826    230      195    429    
  2005‐06                                            771       674             959      360      324    421    115    106    180    222    198    326    463    389      696    258      242    364    
  2006‐07                                            705       607             886      286      245    364    103    95     161    200    179    289    418    357      672    225      207    339    
  2007‐08                                            787       703             1051     324      288    455    154    132    237    252    217    334    452    374      696    272      247    400    
  2008‐09                                            591       558             697      268      250    335    96     79     144    175    142    254    349    289      549    200      179    291    
  Annual mean                                        676       588             968      293      259    406    110    93     191    206    176    327    430    358      738    231      206    374    
  Pandemic                                           2009‐10   1214            1136     1439     765    727    850    291    248    387    368    299    488    664      506    1009     481    431    617
  Respiratory diseases                                                                                                                                                                                 
  Non‐pandemic                                       2001‐02   17 646          15 032   20 971   6354   5860   8221   3760   3524   5011   4270   4056   5259   4323     3978   6441     4820   4607   6097
  2002‐03                                            17 269    14 516          20 494   6204     5490   7469   3939   3782   4894   4447   4202   5696   4593   3973     7781   4913     4620   6514   
  2003‐04                                            15 811    13 558          18 607   5469     4946   6459   3759   3537   4982   4361   4016   5906   4802   4109     8115   4659     4423   6158   
  2004‐05                                            15 207    13 197          17 733   5545     4960   7238   3745   3479   5400   4441   4145   6132   4979   4320     8637   4696     4344   6556   
  2005‐06                                            15 567    14 008          17 688   5919     5407   7423   3946   3732   5123   4669   4468   5820   5246   4664     7806   4953     4671   6335   
  2006‐07                                            15 079    13 905          16 473   5314     5036   6835   3852   3709   4908   4875   4670   5685   5718   5019     7657   4899     4647   6238   
  2007‐08                                            14 844    14 204          16 166   5497     5131   7247   4197   3892   5035   5562   5262   5802   6608   5704     8267   5361     5165   6328   
  2008‐09                                            11 657    11 152          13 254   4740     4415   5972   3355   3124   4350   4612   4319   5165   5733   4855     6871   4466     4298   5412   
  Annual mean                                        15 385    13 696          17 673   5630     5155   7108   3819   3597   4963   4655   4392   5683   5250   4578     7697   4846     4597   6205   
  Pandemic                                           2009‐10   16 469          15 815   17 962   7446   6996   9009   5313   5016   6895   7275   6560   8678   11 541   9669   14 098   7283   6880   8806

Rate is calculated as the sum of estimated outpatient visits divided by the sum of enrollments from 6 participating sites.

CI, denotes confidence interval generated by bootstrap simulation.

Specific ICD‐9‐CM codes for influenza, pneumonia, and respiratory illness categories provided in the Methods.

John Wiley & Sons, Ltd

During the 2009 pandemic, rates for influenza, pneumonia/influenza, and respiratory visits were 173 (95% CI, 154‐207), 481 (95% CI, 431‐617), and 7283 (95% CI, 6880‐8806) per 10 000 person‐years, respectively (Table [2](#irv12495-tbl-0002){ref-type="table-wrap"}). The highest rates for outpatient visits coded for influenza occurred in children aged 2‐17 years, followed by children aged \<2 years; the lowest rates occurred among persons aged ≥65 years. Rates for pneumonia/influenza and respiratory outpatient visits were highest among children aged \<2 years, followed by persons aged 2‐17 years or 65 years and older, while the lowest rate was among adults aged 18‐49 years.

3.1. Estimates of influenza‐associated outpatient visits {#irv12495-sec-0015}
--------------------------------------------------------

Among persons of all ages, the annual mean rate of influenza‐associated visits estimated with models using pneumonia‐coded visits was 39 (95% CI, 30‐70) per 10 000 person‐years during 2001‐02 through 2008‐09. It was 203 (95% CI, 180‐240) per 10 000 person‐years during the 2009 pandemic (Table [3](#irv12495-tbl-0003){ref-type="table-wrap"}). During non‐pandemic and pandemic seasons, rates were higher among younger persons. In pre‐pandemic seasons, the highest rate was 67 (95% CI, 49‐164) per 10 000 person‐years in children aged \<2 years. The lowest rate was 25 (95% CI, 20‐48) for persons aged ≥65 years. The highest rate during the pandemic was 381 (95% CI, 366‐481) in children aged 2‐17 years; the lowest rate was 63 (95% CI, 56‐86) per 10 000 person‐years for individuals aged ≥65 years. We found variability by site as well as by age group in estimated rates, but as no consistent patterns of geographic variability were noted (Table [S1](#irv12495-sup-0001){ref-type="supplementary-material"}), we focused on the clear variability in rates by age group.

###### 

Annual rates of influenza‐associated outpatient visits per 10 000 person‐years estimated with negative binomial regression models, by age group, among 6 US healthcare systems

  Season                                                           Year      Age groups (y)                                                                                                    
  ---------------------------------------------------------------- --------- ---------------- ----- ----- ----- ----- ------ ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  Pneumonia and Influenza[a](#irv12495-note-0007){ref-type="fn"}                                                                                                                               
  Non‐Pandemic                                                     2001‐02   63               46    176   46    36    101    24    13    52    23    15    42    27    22    54    30    21    62
  2002‐03                                                          41        27               117   54    36    123   23     13    39    20    15    33    17    14    31    29    19    56    
  2003‐04                                                          123       83               374   78    50    157   38     20    76    33    18    66    37    25    83    48    29    101   
  2004‐05                                                          56        37               182   49    35    137   29     19    92    30    21    80    28    20    68    34    24    94    
  2005‐06                                                          71        62               125   64    49    116   29     20    46    28    21    40    28    23    42    37    27    58    
  2006‐07                                                          56        45               82    60    55    90    26     23    41    22    18    29    16    14    23    31    29    45    
  2007‐08                                                          90        67               197   96    85    140   70     56    99    57    47    72    33    28    61    67    59    94    
  2008‐09                                                          33        27               62    63    55    101   33     25    43    24    20    29    13    11    22    34    30    46    
  Annual mean                                                      67        49               164   64    50    121   34     24    61    30    22    49    25    20    48    39    30    70    
  Pandemic                                                         2009‐10   302              259   543   381   366   481    186   155   222   131   103   159   63    56    86    203   180   240
  Respiratory diseases                                                                                                                                                                         
  Non‐pandemic                                                     2001‐02   352              285   517   395   341   451    141   115   212   136   122   187   79    65    99    191   170   247
  2002‐03                                                          197       164              411   437   408   591   156    140   245   127   97    218   56    38    129   197   180   298   
  2003‐04                                                          377       338              543   231   161   296   99     49    154   100   65    136   76    55    97    130   84    175   
  2004‐05                                                          297       210              715   564   509   727   192    161   348   186   134   328   93    58    141   256   219   384   
  2005‐06                                                          302       271              387   336   304   381   134    112   181   140   128   159   88    70    94    173   155   202   
  2006‐07                                                          168       160              201   219   198   279   96     82    140   90    78    112   54    48    67    115   103   147   
  2007‐08                                                          261       215              511   544   516   732   235    214   370   221   176   317   117   75    182   277   258   388   
  2008‐09                                                          97        75               242   278   266   347   118    106   180   109   69    171   59    27    112   139   123   197   
  Annual mean                                                      256       215              441   375   338   476   146    122   229   139   109   204   78    54    115   185   161   255   
  Pandemic                                                         2009‐10   460              367   763   954   817   1108   505   414   751   410   297   758   219   116   697   542   441   823

Rate is calculated as the sum of estimated outpatient visits divided by the sum of enrollments from 6 participating sites.

CI, denotes confidence interval generated by bootstrap simulation.

Specific ICD‐9‐CM codes for influenza, pneumonia, and respiratory illness categories provided in the Methods.

John Wiley & Sons, Ltd

The annual mean rate of influenza‐associated visits estimated with models using respiratory‐coded visits was 185 (95% CI, 161‐255) per 10 000 person‐years during pre‐pandemic seasons and 542 (95% CI, 441‐823) per 10 000 person‐years during the pandemic (Table [3](#irv12495-tbl-0003){ref-type="table-wrap"}). During non‐pandemic seasons, the highest rate was 375 (95% CI, 338‐476) per 10 000 person‐years in children aged 2‐17 years, while the lowest rate was 78 (95% CI, 54‐115) in persons aged ≥65 years. Similarly, during the pandemic, the highest rate was in children aged 2‐17 years and the lowest rate was in persons aged ≥65 years.

Age‐specific rates during the pandemic and pre‐pandemic seasons and incidence rate ratios are provided in Figure [1](#irv12495-fig-0001){ref-type="fig"} for estimates made with pneumonia‐coded (Panel A) or respiratory‐coded (Panel B) visits. Substantial increases occurred during the pandemic, most prominently among younger persons. For estimates made with pneumonia visits, the pandemic‐to‐pre‐pandemic ratios were 5.5, 6.0, and 4.5 among persons aged 18‐49 years, 2‐17 years, and \<2 years, respectively. The lowest ratio was 2.6, among persons aged ≥65 years. For estimates made with respiratory visits, a substantial increase in outpatient rates during the pandemic was also noted, although it was smaller. The greatest pandemic/pre‐pandemic ratio was 3.5 among persons aged 18‐49 years (Panel B).

![Estimated rates of outpatient visits in 6 US healthcare delivery organizations (by age group) per 10 000 person‐years (left *y*‐axis) for influenza‐associated pneumonia and influenza (Panel A) and respiratory diseases (Panel B); and pandemic‐to‐pre‐pandemic rate ratios (right *y*‐axis): solid line, rate ratio; dashed line, pandemic rate; and dotted line, pre‐pandemic rate](IRV-12-122-g001){#irv12495-fig-0001}

3.2. Rate comparisons {#irv12495-sec-0016}
---------------------

Our estimates of influenza‐associated outpatient visits among persons aged ≥50 years at Marshfield Clinic were similar to rates of RT‐PCR‐confirmed influenza visits calculated with VE study data (Table [4](#irv12495-tbl-0004){ref-type="table-wrap"}). Rates of RT‐PCR‐confirmed influenza visits each season fell within the 95% CIs of our model‐based estimates in 4 of 5 seasons. During the mild 2005‐06 season, our estimated rate made with pneumonia visits was significantly greater than the rate from the VE study. During the pandemic, rates estimated with pneumonia were similar to rates of RT‐PCR‐confirmed Influenza among subjects enrolled in the IISP. Figure [2](#irv12495-fig-0002){ref-type="fig"} plots our estimated weekly rates and weekly rates of influenza‐associated ILI from IISP. The timing, peak, and magnitude of these rates were consistent among both children aged 0‐17 years and adults aged 18 and older.

###### 

Annual influenza‐associated outpatient visits per 10 000 persons aged ≥50 y at Marshfield Clinic, estimated (i) using negative binomial models with pneumonia and influenza data; and (ii) using RT‐PCR‐confirmed influenza outpatient visits in annual influenza vaccine effectiveness studies

  Season               Negative binomial model‐based estimates   RT‐PCR‐based estimates           
  -------------------- ----------------------------------------- ------------------------ ------- -------
  2005‐06              34.7                                      27.6                     119.0   20.3
  2006‐07              24.3                                      23.0                     105.0   28.5
  2007‐08              125.7                                     108.3                    241.9   150.5
  2008‐09              21.4                                      21.4                     94.1    25.8
  2009 (weeks 40‐44)   40.3                                      40.3                     52.7    39.9

The lower confidence limit is defined by a rate established by visits listing the ICD‐9‐CM code for influenza.

John Wiley & Sons, Ltd

![Estimated weekly rates of outpatient visits per 10 000 persons for influenza‐associated pneumonia and influenza in 6 US healthcare delivery organizations participating in the Vaccine Safety Datalink (VSD) and for influenza‐associated influenza‐like illness outpatient visits from in the Influenza Incidence Surveillance Project (IISP), from October (week 40) 2009 through April (week 20) 2010](IRV-12-122-g002){#irv12495-fig-0002}

4. DISCUSSION {#irv12495-sec-0017}
=============

We estimated influenza‐associated outpatient visit rates in 6 US healthcare organizations enrolling \~7.7 million persons and found that rates were greater among children and young persons during pre‐pandemic and pandemic influenza seasons. The 2009‐10 pandemic was associated with significant increases in rates of influenza‐associated outpatient visits in each of 5 age groups when compared with rates from preceding seasons. These increases were most pronounced in children, as expected.

This pattern of results is consistent with findings from studies of hospitalizations and deaths. One study estimating laboratory‐confirmed US hospitalizations during the 2009‐10 pandemic[22](#irv12495-bib-0022){ref-type="ref"} found that the overall ratio of pandemic to seasonal hospitalizations was 1.7, whereas among persons aged 18‐64 years, the ratio was 4.0, and among children aged 0‐17 years, it was 7.4. Among persons aged ≥65 years, rates of hospitalizations and deaths during the pandemic[22](#irv12495-bib-0022){ref-type="ref"}, [34](#irv12495-bib-0034){ref-type="ref"} were low when compared with seasonal influenza‐associated outcomes.[5](#irv12495-bib-0005){ref-type="ref"}, [6](#irv12495-bib-0006){ref-type="ref"}, [7](#irv12495-bib-0007){ref-type="ref"} Viboud et al[20](#irv12495-bib-0020){ref-type="ref"} suggested that the mean age at death of 37 years during the 2009‐10 pandemic meant that the estimated years of life lost during 2009 alone exceeded those lost during the 1968 pandemic, when the mean age at death was 62 years. Cross‐protective immunity in older persons from prior infections with H1N1 viruses more closely related antigenically to the pandemic strain than H1N1 viruses circulating since 1977 contributed to these findings.[35](#irv12495-bib-0035){ref-type="ref"}

We estimated influenza‐associated outpatient visits by adding influenza‐coded visits to model‐based estimates of influenza‐associated visits in 2 categories: a more restrictive category of outpatient visits coded for pneumonia, and a broader category of visits coded for acute respiratory illnesses. Both categories have been used in studies modeling the burden of influenza‐related illnesses.[5](#irv12495-bib-0005){ref-type="ref"}, [6](#irv12495-bib-0006){ref-type="ref"}, [7](#irv12495-bib-0007){ref-type="ref"}, [16](#irv12495-bib-0016){ref-type="ref"}, [17](#irv12495-bib-0017){ref-type="ref"} It is likely that use of the pneumonia category underestimates the outpatient burden of influenza, because influenza illnesses may be coded for with a variety of ICD‐9‐CM codes, including codes associated with bacterial infections, like bronchitis or sinusitis. It has been proposed that estimates of influenza‐associated pneumonia deaths represent a lower bound of the range of deaths related to influenza infections,[6](#irv12495-bib-0006){ref-type="ref"}, [20](#irv12495-bib-0020){ref-type="ref"} because influenza‐related deaths may represent exacerbations of chronic pulmonary diseases as well. This rationale may also apply to less severe influenza‐associated medical encounters, and therefore, we also made estimates of all respiratory visits that may be related to influenza infections.

Most modeling‐based estimates of serious influenza‐related outcomes (particularly of deaths) cannot be verified because a "gold standard" for laboratory‐confirmed late sequelae is lacking. By contrast, we compared our estimated outpatient rates with those made in 2 studies that prospectively enrolled and tested outpatients for influenza infection with RT‐PCR (ie, gold standard) methods. Our estimates of outpatient rates made using pneumonia‐coded visits in adults aged ≥50 years at Marshfield Clinic were compared with those derived from a series of annual VE studies conducted there. Our rates were statistically consistent with rates of RT‐PCR‐confirmed influenza visits during 4 of 5 seasons. During the mild 2005‐06 influenza season, when few patients enrolled in Marshfield\'s VE study,[33](#irv12495-bib-0033){ref-type="ref"} our model‐based estimate of 35 visits per 10 000 person‐years was significantly greater than the RT‐PCR‐confirmed estimate of 20 visits per 10 000 person‐years. There are several possible reasons for this finding. First, because of the relative paucity of influenza activity during 2005‐06, we may have attributed illnesses to influenza that were associated with other acute respiratory pathogens. Most patients tested for influenza with RT‐PCR at Marshfield Clinic were recruited by staff based on chief complaints of fever or respiratory symptoms, and not on the basis of ICD‐9‐CM diagnosis codes recorded after medical care. It is possible also that during milder influenza seasons, ICD codes may be less useful for identifying influenza cases. Based on these comparisons, we believe that future modeling studies should attempt to include more mild influenza seasons, as data from a broad range of seasons should permit better calibration of statistical models, and prevent possible overestimation of influenza‐mediated events.

The second source of PCR‐confirmed data was limited to the pandemic season. Estimated rates based on pneumonia‐coded visits in the 6 participating sites were broadly consistent with rates of RT‐PCR‐confirmed influenza in the IISP study, which tested outpatients presenting with ILI.[23](#irv12495-bib-0023){ref-type="ref"} As the ILI syndrome likely does not detect all illnesses that may be associated with influenza infections, this PCR‐based estimate is conservative, suggesting that our pneumonia‐based estimates are also conservative. Data from studies using sensitive diagnostics among a more inclusive set of signs and symptoms of influenza would be helpful.

More model‐based estimates of influenza‐associated outpatient visits should be compared with data from studies using RT‐PCR or other highly sensitive diagnostics. The generalizability of this study\'s findings (and its underlying models) is limited by the paucity of comparison data. For example, the pandemic season was unusual---increased healthcare utilization consistent with intense media coverage was noted in 1 study site[36](#irv12495-bib-0036){ref-type="ref"}---and comparisons made then may not be applicable during interpandemic periods. In Marshfield, comparison data were available only for older adults. Overall, our results suggest that models developed for more severe influenza outcomes yield influenza outpatient rate estimates that appear consistent with rates calculated with data collected in protocol‐based studies using state‐of‐the‐art diagnostics.

Our estimated rates of influenza‐associated outpatient are somewhat lower than rates reported in some other studies. Poehling et al[17](#irv12495-bib-0017){ref-type="ref"} reported that among children aged \<2 years in 3 sites, the incidence of outpatient visits attributable to influenza among children was 280‐520 per 10 000 during 2002‐03 and 590‐1250 per 10 000 during 2003‐04. For the same age group, we estimated influenza‐associated respiratory visit rates were 197 per 10 000 and 377 per 10 000 in these 2 seasons, respectively. Besides the usual caveats regarding differences in study design affecting incidence estimates, it is possible that geographic differences in influenza activity also affected these comparisons. Poehling\'s study had 3 sites and ours 6; neither had the population size or geographic variation for its estimates to be interpreted as national in scope. We did find variation among our sites in estimated rates (Table [S1](#irv12495-sup-0001){ref-type="supplementary-material"}); however, no clear age‐specific patterns of differences by geography were apparent. Although estimated rates may be difficult to compare because of differences in study design, populations studied, seasons included, and geography, rate ratios between age groups should be similar. Here our findings are consistent with those from other studies[12](#irv12495-bib-0012){ref-type="ref"}, [14](#irv12495-bib-0014){ref-type="ref"}, [15](#irv12495-bib-0015){ref-type="ref"}, [16](#irv12495-bib-0016){ref-type="ref"}, [17](#irv12495-bib-0017){ref-type="ref"}, [23](#irv12495-bib-0023){ref-type="ref"}: Young children bear the brunt of the outpatient influenza burden. Finally, although our study included \>7 million persons, a larger population than other US studies, all data were from integrated health systems. Thus, at least with respect to age, our population is unlikely to fully represent the US population.[27](#irv12495-bib-0027){ref-type="ref"} The generalizability of our findings to other US populations, like the uninsured and those covered by the Department of Veterans Affairs, may be more limited.

In addition to the issues noted above, we acknowledge other limitations. While we did adjust for RSV activity by including a weekly term for this virus in all models, we could not consider the effects of other viral or bacterial respiratory pathogens on influenza estimates. Because RSV circulation often overlaps with influenza circulation and it is the leading cause of infectious respiratory disease among in young children,[6](#irv12495-bib-0006){ref-type="ref"}, [37](#irv12495-bib-0037){ref-type="ref"} we emphasized adjusting for regional RSV activity. Because the onset, duration, and intensity of influenza virus circulation vary geographically,[38](#irv12495-bib-0038){ref-type="ref"} aggregating virus surveillance data by the US region of each site may not adequately capture the variability in timing of influenza virus circulation.

Few studies have estimated annual rates of laboratory‐confirmed influenza outpatient visits. None cover the full age spectrum, include many influenza seasons, and represent national‐level populations. Because prospective studies that consent and enroll subjects are resource‐intensive, we suggest that modeling methods similar to those used here deserve further exploration and validation for use in estimating outpatient influenza rates. These methods are less expensive and may provide reasonably sensitive, specific, and timely estimates of the influenza‐associated outpatient disease burden. Regular assessments of the burden of annual epidemics and occasional pandemics are crucial for quantifying the potential benefits of influenza prevention and treatment modalities over time. Such assessments need to include influenza‐associated outpatient medical visits in addition to hospitalization and deaths.
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